Skip to content
Markets News
Stocks1 min read

Supernus and Indivior Merger Closes, Ticker Switch Set for Tuesday

Makkler Newsroom
November 2, 2026 · Based on reporting by GlobeNewswire

The combined company will trade as INDV on Nov. 2 before switching to SUPN on the Nasdaq Global Market the next day.

Key takeaways

  • Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on Nov. 2.
  • Former Indivior shareholders own about 56.5% of the combined company.

Supernus Pharmaceuticals and Indivior Pharmaceuticals have completed their merger, creating a combined company called Supernus, Inc. The company will trade under INDV on Nov. 2 and is expected to switch to SUPN on the Nasdaq Global Market on Nov. 3.

Former Indivior shareholders own about 56.5% of the combined company, while former Supernus Pharmaceuticals shareholders own about 43.5%, on a fully diluted basis. Under the deal terms, Supernus Pharmaceuticals shareholders received 1.5401 Indivior shares for each share they held.

Indivior shareholders are to receive a one-time special cash dividend of $1 billion in total. The companies said they used a $650 million term loan facility from Citibank and existing cash to fund it.

The combined company has an 11-product portfolio spanning opioid use disorder, psychiatry and neurology. Jack Khattar is its president and chief executive, and Supernus Pharmaceuticals’ Rockville, Maryland, headquarters will serve as its global headquarters.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.